Journal article
Genetic Analysis of Multiple Myeloma Identifies Cytogenetic Alterations Implicated in Disease Complexity and Progression
Cancers, Vol.13(3), pp.1-15
02/01/2021
DOI: 10.3390/cancers13030517
PMCID: PMC7866300
PMID: 33572851
Abstract
Simple Summary
Multiple myeloma (MM) is the second most common hematological neoplasia with a high incidence in elderly populations. The disease is characterized by a severe chaos of genomic abnormality. Comprehensive examinations of myeloma cytogenetics are needed for better understanding of MM and potential application to the development of novel therapeutic regiments. Here we utilized gene expression profiling and CytoScan HD genomic arrays to investigate molecular alterations in myeloma leading to disease progression and poor clinical outcomes. We demonstrates that genetic abnormalities within MM patients exhibit unique protein network signatures that can be exploited for implementation of existing therapies targeting key pathways and the development of novel therapeutics.
Multiple myeloma (MM) is a genetically heterogeneous disease characterized by genomic chaos making it difficult to distinguish driver from passenger mutations. In this study, we integrated data from whole genome gene expression profiling (GEP) microarrays and CytoScan HD high-resolution genomic arrays to integrate GEP with copy number variations (CNV) to more precisely define molecular alterations in MM important for disease initiation, progression and poor clinical outcome. We utilized gene expression arrays from 351 MM samples and CytoScan HD arrays from 97 MM samples to identify eight CNV events that represent possible MM drivers. By integrating GEP and CNV data we divided the MM into eight unique subgroups and demonstrated that patients within one of the eight distinct subgroups exhibited common and unique protein network signatures that can be utilized to identify new therapeutic interventions based on pathway dysregulation. Data also point to the central role of 1q gains and the upregulated expression of ANP32E, DTL, IFI16, UBE2Q1, and UBE2T as potential drivers of MM aggressiveness. The data presented here utilized a novel approach to identify potential driver CNV events in MM, the creation of an improved definition of the molecular basis of MM and the identification of potential new points of therapeutic intervention.
Details
- Title: Subtitle
- Genetic Analysis of Multiple Myeloma Identifies Cytogenetic Alterations Implicated in Disease Complexity and Progression
- Creators
- Can Li - University of Arkansas for Medical SciencesErik B. Wendlandt - University of IowaBenjamin Darbro - Roy J. and Lucille A. Carver College of MedicineHongwei Xu - University of Arkansas for Medical SciencesGregory S. Thomas - University of IowaGuido Tricot - University of Arkansas for Medical SciencesFangping Chen - Xiangya Hospital Central South UniversityJohn D. Shaughnessy - University of Arkansas for Medical SciencesFenghuang Zhan - University of Arkansas for Medical Sciences
- Resource Type
- Journal article
- Publication Details
- Cancers, Vol.13(3), pp.1-15
- DOI
- 10.3390/cancers13030517
- PMID
- 33572851
- PMCID
- PMC7866300
- NLM abbreviation
- Cancers (Basel)
- ISSN
- 2072-6694
- eISSN
- 2072-6694
- Publisher
- Mdpi
- Number of pages
- 14
- Grant note
- R01CA236814 / National Cancer Institute; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI) TRP 6549-18 / Leukemia and Lymphoma Society CA180190 / US Department of Defense; United States Department of Defense UAMS Winthrop P. Rockefeller Cancer Institute start-up Myeloma Crowd Research Initiative Award
- Language
- English
- Date published
- 02/01/2021
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Stead Family Department of Pediatrics; Medical Genetics and Genomics; Medicine Administration; Internal Medicine
- Record Identifier
- 9984353802702771
Metrics
13 Record Views